EG-70
BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS)
Key Facts
Indication
BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS)
Phase
Phase 1/2
Status
Active, Recruiting
Company
About enGene
enGene is a Canadian biotech focused on creating a new class of genetic medicines using its proprietary non-viral gene delivery platform. The company's lead program, EG-70, is in clinical development for non-muscle invasive bladder cancer (NMIBC), aiming to overcome the limitations of current viral vector-based therapies. enGene leverages its platform to target mucosal tissues with high efficiency and localized effect, potentially addressing a range of diseases. The company went public in 2023 to fund its clinical advancement and platform expansion.
View full company profileTherapeutic Areas
Other BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cretostimogene grenadenorepvec | CG Oncology | Phase 3 |